About Resolution Therapeutics
Resolution Therapeutics is a company based in Edinburgh (United Kingdom) founded in 2017 by John Campbell and Stuart Forbes. Resolution Therapeutics has raised $119.88 million across 2 funding rounds from investors including Syncona. The company has 6 employees as of March 31, 2021. Resolution Therapeutics offers products and services including RTX001 and Macrophage Cell Therapies. Resolution Therapeutics operates in a competitive market with competitors including Aclaris Therapeutics, NGM Biopharmaceuticals, Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences, among others.
- Headquarter Edinburgh, United Kingdom
- Employees 6 as on 31 Mar, 2021
- Founders John Campbell, Stuart Forbes
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Resolution Therapeutics Limited
- Date of Incorporation 14 Dec, 2017
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
-$4.95 M (USD)-254as on Mar 31, 2022
-
EBITDA
-$5.39 M (USD)-285as on Mar 31, 2022
-
Total Equity Funding
$119.88 M (USD)
in 2 rounds
-
Latest Funding Round
$84.3 M (USD), Series B
Oct 03, 2024
- Investors
-
Employee Count
6
as on Mar 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Resolution Therapeutics
Resolution Therapeutics offers a comprehensive portfolio of products and services, including RTX001 and Macrophage Cell Therapies.
Treats end-stage liver disease using regenerative macrophages for organ repair.
Addresses inflammatory organ damage through engineered cell-based treatments.
People of Resolution Therapeutics
Unlock access to complete
Funding Insights of Resolution Therapeutics
Resolution Therapeutics has successfully raised a total of $119.88M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $84.3 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Resolution Therapeutics
Resolution Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Syncona.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are managed via private equity by Syncona.
|
Locked | Locked | Locked |
Investor details for Resolution Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Resolution Therapeutics
Investment portfolio details for Resolution Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Resolution Therapeutics
Detailed financials for Resolution Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Resolution Therapeutics Comparisons
Peer comparison for Resolution Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Resolution Therapeutics
Resolution Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, NGM Biopharmaceuticals, Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
Detailed competitors of Resolution Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Resolution Therapeutics
Complete news archive for Resolution Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Resolution Therapeutics
Resolution Therapeutics was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Resolution Therapeutics is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Resolution Therapeutics is a funded company, having raised a total of $119.88M across 2 funding rounds to date.
As of Mar 31, 2021, the latest employee count at Resolution Therapeutics is 6.
Resolution Therapeutics was founded in 2017 in Edinburgh, United Kingdom, focusing on biotechnology. Cell therapies based on macrophage biology, engineering, and manufacturing processes are developed by the company. These therapies target inflammatory and liver diseases by enhancing immune responses, preventing organ damage from inflammation, aiding wound sterilization, and supporting organ repair. Operations center on proprietary platforms for therapeutic solutions in this sector.
Resolution Therapeutics's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Resolution Therapeutics offers RTX001 and Macrophage Cell Therapies.
Resolution Therapeutics has 1 investor. Key investors include Syncona.